Bi-Weekly UpdateSep 28, 2026 · 7 pages · Free to read

Cell and Gene Therapies Bi-Weekly Industry Events & M&A Update — September 14–28, 2026

A bi-weekly read on cell and gene therapies covering share-price moves, major news catalysts and M&A activity from September 14–28, 2026, for operators, acquirers and advisors tracking platform-level versus program-level value in the sector.

Download PDF Download PowerPoint

-5.7%
Sector median move: +0.8%
S&P 500 return: +14.0%
Precigen (PGEN) share move: 14.4x
EV/Revenue CY2027E median

1 of 7

$C:\Users\dawoo\OneDrive\Desktop\Deployments\neuracap_sector_reports_fable\Code\NeuraCap_Sector_Report_Pipeline_v2.1.0\ncsr\deck_kit\assets\logo_light_full.png$

BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE

HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › CELL AND GENE THERAPIES

Platform Proof Earns a Bid While Program Timelines Get Marked Down

What moved, what companies did and what was agreed across cell and gene therapies from September 14–28, 2026.

September 14–28, 2026

Prepared by NeuraCap AI   ·   Confidential

Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28

Cell and Gene Therapies Bi-Weekly Update   |   September 14–28, 2026   |   Confidential   |   Not investment advice

Sources & methodology

1

1 / 7 · HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › CELL AND GENE THERAPIES

Executive summary

Across September 14–28, 2026, cell and gene therapy shares sold off broadly: 32 of 43 covered names fell against a sector median of -5.7%, while the S&P 500 returned +0.8%. The clearest gain came from a platform-level regulatory designation; the steepest declines followed program-specific disclosures. The period's one agreed deal, Lexeo Therapeutics' acquisition of Mantle Therapeutics, priced pipeline breadth rather than near-term earnings — extending NeuraCap's view that platform credentials and program-stage exposure now trade on different terms.

Key findings

Selling was broad: 32 of 43 covered names fell over the two-week period.
Platform designation was the clearest upside catalyst, with PGEN up +14.0%.
Registrational disclosures drove the steepest declines, including CABA -31.3%.
One agreed deal: Lexeo agreed to acquire Mantle Therapeutics, adding pipeline breadth.

What each page shows

The analyst’s walkthrough of the deck, page by page.

01
BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE
HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › CELL AND GENE THERAPIES
Cover slide introducing the Cell and Gene Therapies bi-weekly industry events and M&A update for September 14–28, 2026.
This report covers what changed, who moved and most likely why, what transacted, and what it means across cell and gene therapies for September 14–28, 2026. We built it to give you a fast, evidence-based read before your next client conversation.
Everything on this page
BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › CELL AND GENE THERAPIES Platform Proof Earns a Bid While Program Timelines Get Marked Down What moved, what companies did and what was agreed across cell and gene therapies from September 14–28, 2026. September 14–28, 2026 Prepared by NeuraCap AI · Confidential Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28 Cell and Gene Therapies Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 1
02
THE BI-WEEKLY BOTTOM LINE
Validated Platform Credentials Were Paid For
Summarizes the two-week period across 43 covered names on a close-to-close basis.
We tracked 43 covered names across cell and gene therapies over September 14–28, 2026, and the median move was -5.7% against a S&P 500 return of +0.8%. That gap tells us the sector sold off broadly rather than in isolated pockets. The clearest standout was a platform-level regulatory event, not a single trial readout, so we read this as the market paying for durable platform credentials over one-off data. For clients, that means the premium is attaching to reusable technology, not to any single program's news flow.
Everything on this page
THE BI-WEEKLY BOTTOM LINE Validated Platform Credentials Were Paid For The two-week period in one page · 43 covered names, close-to-close · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Driver attributions use calibrated language and are NeuraCap reads of the recorded evidence. Cell and Gene Therapies Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 2 1 Selling Was Broad Across the Covered Group, Not Selective 32 of 43 covered names fell; the median move was -5.7%, while the S&P 500 returned +0.8% over the same two-week period. 2 A Platform Designation Was the Clearest Upside Event of the Period Precigen, Inc. (PGEN), a Core-tier name, gained +14.0%, with its strongest session of +6.3% on September 16 and a 52-week high of $8.04 on September 23. 3 Registrational Detail Moved the Biggest Names Down Hardest Rocket Pharmaceuticals, Inc. (RCKT) fell -23.9% and Lexeo Therapeutics (LXEO) fell -25.4%, each alongside its own in-window disclosure. Cabaletta Bio, Inc. (CABA) at -31.3% and Artiva Biotherapeutics, Inc. (ARTV) at -30.5% were the steepest declines in the set. 4 One Agreed Transaction Landed, and It Was Pipeline Breadth Rather than Earnings Lexeo Therapeutics (LXEO) agreed to acquire Mantle Therapeutics and announced new Friedreich ataxia collaborations on September 22. It is the only transaction the companies themselves announced as agreed in the window. +18.7% Best mover — IOVA worst: CABA -31.3% · 11 up / 32 down of 43 covered -5.7% Sector median two-week return vs S&P 500 +0.8% 1 Transaction agreed in the two-week period from company announcements; not yet in the precedent record 3 Company filings in the window 8-K events read for driver attribution
03
PUBLIC MARKET MOVERS
Platform Credentials Travelled Well; Program Mechanics and Deal News Did Not
Shows individual company share-price moves against the sector median and market benchmark for the period.
Precigen led the group at +14.0%, while Rocket Pharmaceuticals fell -23.9%, Lexeo Therapeutics fell -25.4%, Cabaletta Bio fell -31.3% and Artiva Biotherapeutics fell -30.5% — all against a sector median of -5.7% and a materiality bar of 11.8%. We attribute each move only to the filings and headlines recorded in the window, and where no driver is on record we say so. The pattern is consistent: platform-level catalysts moved names up, and program-specific disclosures moved names down hardest. So what: the split is now wide enough that generalized sector coverage undersells both the winners and the risks.
Everything on this page
PUBLIC MARKET MOVERS Platform Credentials Travelled Well; Program Mechanics and Deal News Did Not Bi-Weekly moves, close-to-close · September 14–28, 2026 · sector median -5.7% · S&P 500 +0.8% · materiality bar ±11.8% (sector-relative) Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Attribution links each move only to filings and headlines recorded in the window; where no driver is recorded, the page says so. Calibrated language throughout — NeuraCap reads, not asserted causation. Cell and Gene Therapies Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 3 Bi-Weekly return per company · teal above zero, amber below · sector median -5.7% Cabaletta Bio, Inc. (CABA) -31.3% No notable in-window news was identified that clearly explains the move. Cabaletta Bio, Inc. (CABA) fell -31.3% against a sector median of -5.7%. Clinical-stage names carry the widest two-week dispersion in this set, in both directions. UNEXPLAINED Artiva Biotherapeutics, Inc. (ARTV) -30.5% No notable in-window news was identified that clearly explains the move. Artiva Biotherapeutics, Inc. (ARTV) fell -30.5% against a sector median of -5.7%, with its steepest session of -12.1% on September 15. Allogeneic developers moved with the group's risk appetite more than with their own disclosure flow. UNEXPLAINED Lexeo Therapeutics, Inc. Common Stock (LXEO) -25.4% Shares moved following the September 22 agreement by Lexeo Therapeutics (LXEO) to acquire Mantle Therapeutics and launch new Friedreich ataxia collaborations; the steepest session, -13.5%, came the next day. Buying added modalities around a lead program can be read as breadth or as spend; this Core-tier name got the second read. COMPANY-SPECIFIC Iovance Biotherapeutics, Inc. (IOVA) +18.7% No notable in-window news was identified that clearly explains the move. Iovance Biotherapeutics, Inc. (IOVA) rose +18.7% while the median covered name fell -5.7%. A Core-tier name can lead the group over a two-week period without a catalyst sitting in the record. UNEXPLAINED
04
MAJOR NEWS & INDUSTRY CATALYSTS
A Commercial-Stage Leadership Change, and a Data-Package Dispute That Stayed in the News
Ranks the two-week period's highest-impact news events with sourcing links and NeuraCap's read on why each mattered.
This page ranks the period's highest-impact events, each linked back to the underlying filing or article. We wrote a 'why it matters' read for every item, drawing only on SEC filings, press releases and established outlets. The two events that carried the most weight were a commercial-stage leadership change and a data-package dispute that stayed in the news across the window. So what: these are the two threads worth raising first in any client conversation about the sector's near-term footing.
Everything on this page
MAJOR NEWS & INDUSTRY CATALYSTS A Commercial-Stage Leadership Change, and a Data-Package Dispute That Stayed in the News The two-week period's highest-impact events · titles link to the underlying filing or article · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. "Why it matters" lines are NeuraCap reads; each event links to its source. Sources are admitted in a fixed reliability order (SEC filings, press releases, established outlets); video and social platforms are never used. Cell and Gene Therapies Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 4 Sep 15 · 8-K · SEC EDGAR Legend Biotech appointed Ingrid Zhang chief executive, effective September 15, 2026 A change at the top of a commercial-stage cell therapy company sets the agenda for launch execution — authorized treatment centre activations, vein-to-vein time and cost of goods per dose. Leadership transitions at commercial-stage names read as launch-velocity decisions, not only pipeline decisions. Sep 15 · NEWS · PRNewsWire Capricor Therapeutics (CAPR) faces a securities class action over its Deramiocel data package The claim centres on alleged misstatements about Deramiocel and the integrity of the clinical data supporting the Biologics License Application, following a 64% stock drop. Data-package readiness is a valuation variable alongside efficacy, not downstream of it. Sep 15 · NEWS · Newsfile Corp Kaplan Fox urged Capricor investors to come forward before the September 28 lead-plaintiff deadline The notice fixes a near-term procedural date on the docket for a Discount-tier name. Legal calendars of this kind sit alongside the clinical calendar that usually drives sentiment here. For contested filings, the legal timetable becomes one more dated item investors track. Sep 15 · NEWS · PRNewsWire Hagens Berman flagged the September 28 deadline to lead the Capricor shareholder class action Multiple firms circulating the same deadline suggests an institutionally held register paying attention to the outcome. That shapes how the shareholder base behaves around future disclosure. Register composition influences how hard a disputed regulatory setback gets pressed. Sep 15 · NEWS · GlobeNewsWire Bernstein Liebhard reminded Capricor investors of the September 28 class action deadline The repetition keeps the dispute in front of the market through the back half of the two-week period. Unresolved questions about a submission tend to hold a discount in place. Open regulatory disputes tend to persist in the price until the process itself clears. Sep 15 · NEWS · GlobeNewsWire Portnoy Law Firm announced a class action on behalf of Capricor investors over a defined purchase window Defining the purchase window frames the period of disclosure under challenge. For peers, the relevant read is how tightly submission status and communicated timelines are kept aligned. Communicated regulatory timelines and actual submission status are held to the same standard.
05
M&A & STRATEGIC ACTIVITY
Lexeo Agrees to Buy Mantle Therapeutics and Stacks Collaborations Around Friedreich Ataxia
Details the period's one agreed acquisition and new collaboration announcements, set against 40 recorded precedent transactions.
Lexeo Therapeutics agreed to acquire Mantle Therapeutics and announced new Friedreich ataxia collaborations, the only transaction the companies themselves announced as agreed in this window. We benchmark it against a trailing record of 40 recorded precedent transactions, using LTM multiples at announcement where disclosed. The deal is structured around added modalities and collaborations in one indication, which we read as pipeline breadth being purchased rather than near-term earnings. So what: this is the reference point to use when a client asks what a credible bid for platform breadth looks like right now.
Everything on this page
M&A & STRATEGIC ACTIVITY Lexeo Agrees to Buy Mantle Therapeutics and Stacks Collaborations Around Friedreich Ataxia September 14–28, 2026 · 1 agreed by company announcement · precedent transactions: 40 recorded deals Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Deal multiples are LTM at announcement where disclosed; "why the deal happened" is a NeuraCap read of the recorded evidence. No old transactions are re-presented as news. Cell and Gene Therapies Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 5 AGREED IN THE PERIOD — FROM COMPANY ANNOUNCEMENTS Sep 22 · Lexeo Therapeutics, Inc. Common Stock (LXEO) Lexeo Therapeutics (LXEO) agrees to acquire Mantle Therapeutics and adds new Friedreich ataxia collaborations The stated logic is added modalities designed to increase or replace frataxin in the brain, plus collaborations evaluating sequential gene therapy dosing after treatment with its lead program. Terms and multiples enter the precedent record once the filing is processed; the reference set alongside is unchanged. 40 Recorded precedent transactions the reference set buyers and sellers price against
06
WHAT IT MEANS
What This Two-Week Period Changes for Operators, Buyers and Advisors
Translates the period's evidence into observations for owners, acquirers and advisors.
For owners and operators, the evidence that earned a bid was platform-level and operational, not a single readout. For acquirers, the Lexeo-Mantle agreement prices breadth rather than earnings, adding a fresh data point to the precedent set. For advisors, the theme to carry forward is the split itself: platform validation and commercial-stage supply are being valued on different terms from clinical single-asset exposure. So what: each audience has a distinct action to take from the same two weeks of evidence.
Everything on this page
WHAT IT MEANS What This Two-Week Period Changes for Operators, Buyers and Advisors The two-week period translated for the people who act on it · NeuraCap view · observations, not recommendations Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. This page is analytical interpretation drawn from the two-week period's recorded evidence. It is not investment advice. Cell and Gene Therapies Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 6 Sector study 2026-09-28 EV / Revenue (CY2027E) median 14.4x 47 companies in the study 3 valuation tiers Standing thesis: Cell and Gene Therapies Trades as Two Markets: Platform Developers and Commercial-Stage Supply FOR OWNERS & OPERATORS The Evidence That Earned a Bid Was Platform-Level and Operational The period rewarded a designation attached to a reusable platform rather than a single readout. FOR ACQUIRERS One Agreed Transaction, and It Prices Breadth Rather than Earnings The Lexeo Therapeutics (LXEO) agreement to acquire Mantle Therapeutics adds a fresh reference point to a trailing record of 40 precedent transactions, and it is structured around added modalities and collaborations in one indication. FOR ADVISORS Lead with the Split, Not the Midpoint The theme to carry into conversations is that platform validation and commercial-stage supply are being valued on different terms from clinical single-asset exposure.
07
SOURCES & METHODOLOGY
Sources, Methodology and Important Notice
Explains the data sources, methodology and limitations behind every figure in the update.
Every figure in this update links back to the record it was taken from, and the publishers and filings we drew on for the period are listed on this page. We use a fixed reliability order for sourcing — SEC filings first, then press releases, then established outlets — and calibrated language throughout rather than asserted causation. This page also carries a formal notice that the update is analytical interpretation, not investment advice. So what: it's the page to point to whenever a client asks how we built any specific figure.
Everything on this page
SOURCES & METHODOLOGY Sources, Methodology and Important Notice How this bi-weekly update is built and what each kind of statement rests on · September 14–28, 2026 · market data through 2026-09-28 Every figure in this update links to the record it was taken from; the publishers and filings drawn on for the period are listed above. Cell and Gene Therapies Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice 7 OBSERVED DATA Bi-Weekly stock moves are computed close-to-close over the stated window from the platform’s price series. Deal records, values and multiples come from the platform’s transaction record (SEC 8-K extractions) exactly as recorded; each figure links to its citation. Treasury rates come from the platform’s Treasury series and are shown only when the 10-year moved at least ten basis points over the window (it did not in this window, so no rate figures appear). UNIVERSE QUALITY The update universe is the platform’s approved company set for this sector, subject to a $100M market-cap floor so small, loosely related names cannot dominate the statistics. 4 names below the floor were excluded from movers and statistics for this window. EVENTS & NEWS Company events are in-window 8-K filings; news items are publisher-sourced headlines fetched for the window (and any externally supplied items, marked as such). Operational and strategic developments (deals, partnerships, launches, expansion, guidance, leadership, regulatory outcomes) are shown first; capital-return mechanics and conference appearances are limited to one each. Every event links to its source. The deck never asserts an event that has no linked record. SOURCE HIERARCHY News is admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then transaction documents, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron’s and peers). Video and social platforms — including YouTube — are never used as sources. DRIVER ATTRIBUTION A stock move is linked to an event only when the event falls inside the window, and only in calibrated language ("the move appears to reflect…", "shares moved following…"). Where no driver is recorded, the page says so and compares the move to the sector median instead. ANALYTICAL INTERPRETATION "Why it matters", "why the deal happened" and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, and are labeled as such. INHERITED CONTEXT The standing sector view (thesis, valuation lens, sector median and tiering) is inherited from the NeuraCap sector study run_20260929T183126Z_561_prod (market data as of 2026-09-28) — distilled, never re-derived. That report’s own sources page governs its content; this update reads the period against it. IMPORTANT NOTICE This report is informational only. It is not investment advice, not a recommendation to buy or sell any security, and not an offer of any kind. Readers should perform their own diligence before acting on anything described here. Linked sources this two-week period: sec.gov · prnewswire.com · newsfilecorp.com · globenewswire.com

Sources and methodology

This update covers Cell and Gene Therapies over the 14-day window September 14–28, 2026; market data runs through September 28, 2026. The universe is the 43 listed companies whose core business is Cell and Gene Therapies under NeuraCap's industry classification, subject to a $100M market-capitalisation floor so that very small, loosely related names cannot dominate the movers and statistics. Companies covered: Abeona Therapeutics Inc. (ABEO), Allogene Therapeutics, Inc. (ALLO), Artiva Biotherapeutics, Inc. (ARTV), Autolus Therapeutics plc (AUTL), Beam Therapeutics Inc. (BEAM), Cabaletta Bio, Inc. (CABA), Candel Therapeutics, Inc. (CADL), Capricor Therapeutics, Inc. (CAPR), CG Oncology Inc. (CGON), CRISPR Therapeutics AG (CRSP), Dyne Therapeutics, Inc. (DYN), enGene Holdings Inc. (ENGN), Fate Therapeutics, Inc. (FATE), 4D Molecular Therapeutics, Inc. (FDMT), Immix Biopharma, Inc. (IMMX), Immatics N.V. (IMTX), Iovance Biotherapeutics, Inc. (IOVA), Opus Genetics, Inc. (IRD), Krystal Biotech, Inc. (KRYS), Kyverna Therapeutics, Inc. (KYTX), Legend Biotech Corporation (LEGN), Lexeo Therapeutics, Inc. Common Stock (LXEO), Mesoblast Limited (MESO), Neurogene Inc. (NGNE), Nkarta, Inc. (NKTX), Intellia Therapeutics, Inc. (NTLA), Ocugen, Inc. (OCGN), Precigen, Inc. (PGEN), Prime Medicine, Inc. (PRME), ProKidney Corp. (PROK), uniQure N.V. (QURE), Rocket Pharmaceuticals, Inc. (RCKT), Replimune Group, Inc. (REPL), REGENXBIO Inc. (RGNX), Cartesian Therapeutics, Inc. (RNAC), Sana Biotechnology, Inc. (SANA), Solid Biosciences Inc. (SLDB), Takeda Pharmaceutical Company Limited (TAK), Protara Therapeutics, Inc. (TARA), Tenaya Therapeutics, Inc. (TNYA), Taysha Gene Therapies, Inc. (TSHA), Vericel Corporation (VCEL), Vor Biopharma Inc. (VOR). 4 names below the floor were excluded from the statistics: ALPS, ANIX, INKT, KRRO.

Window and company universe

How the moves and statistics are computed

Each company's period move is the change in closing price from the last close before the window to the last close inside it (close-to-close). The sector median is the median of those moves across the covered names; the index return is computed the same way for the S&P 500 over the same dates. The largest single-day move inside the window is shown for each mover. Movers are the largest gainers and losers by period move; the attribution cards prefer movers whose in-window record explains the move. Movers carry the valuation tier assigned in the standing sector study (the latest NeuraCap sector outlook) where that study rated them.

Events, news and how a move is attributed

Company events are the 8-K filings made inside the window; news items are publisher-sourced headlines for the window, admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron's and peers). Video and social platforms are never used. A move is linked to an event only when the event falls inside the window and only in calibrated language; where nothing in the record explains a move, the update says so rather than speculating. Every event links to its source.

Transactions in the window and the trailing record

Transactions are taken from SEC filings by announcement date; 0 were announced inside the window. The trailing record of 40 recorded transactions provides the reference multiples (EV over last-twelve-month revenue or EBITDA at announcement, as disclosed). A value whose own citation describes something other than the price paid is not shown as the deal value; transactions where the acquirer and the target are the same entity are treated as reorganisations and excluded.

Sources

Prices and index levels are market data through September 28, 2026; filings are the companies' SEC filings on EDGAR; press releases are the companies' own; other news items are from the established outlets named on each card; Treasury yields are published by the U.S. Department of the Treasury. Every figure and every event in the update links to its record.

Interpretation and important notice

'Why it matters', 'why the deal happened' and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, labelled as such. The update is informational: it is not investment advice, not a recommendation to buy or sell any security and not an offer of any kind.

This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.

More coverage in Health Care

Want this analysis for a company in Cell and Gene Therapies?

Company valuation reports run the same method against a single business — public or private.

Get your report Talk to advisory

Cell and Gene Therapies Bi-Weekly Industry Events & M&A Update — September 14–28, 2026

Key figures

Read the report

Executive summary

Key findings

What each page shows

HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › CELL AND GENE THERAPIES

Validated Platform Credentials Were Paid For

Platform Credentials Travelled Well; Program Mechanics and Deal News Did Not

A Commercial-Stage Leadership Change, and a Data-Package Dispute That Stayed in the News

Lexeo Agrees to Buy Mantle Therapeutics and Stacks Collaborations Around Friedreich Ataxia

What This Two-Week Period Changes for Operators, Buyers and Advisors

Sources, Methodology and Important Notice